The Weizmann Institute of Science congratulates Prof. Ada Yonath on receiving the 2009 Nobel Prize in chemistry and is proud of her scientific achievements. We are delighted that the Nobel Prize committee has recognized the significance of Prof. Ada Yonath’s scientific research and awarded her this important prize.
Prof. Yonath’s research is driven by curiosity and ambition to better understand the world and our place within it. This research aims high: to understand one of the most complicated ‘machines’ of the biological system.
In the late 1970s, Prof. Yonath decided, when she was a young student at the Weizmann Institute, to take on the challenge of answering one of the key questions concerning the activities of live cells: to decipher the structure and mechanism of action of ribosomes – the cell’s protein factories. This was the beginning of a long scientific journey that has lasted decades, and which required courage and devotion from the start. The journey began in a modest laboratory with a modest budget, and with the years, increased to tens of researchers under the guidance of Prof. Yonath.
This basic research, which began in the attempt to understand one of the principles of nature, eventually led to the understanding of how a number of antibiotics function, something that is likely to aid in the development of more advanced and effective antibiotics. This discovery will hopefully also help in the struggle against antibiotic-resistant bacteria, a problem recognized as one of the most central medical challenges of the 21st century.
Prof. Yonath can be considered a model of scientific vision, courage in choosing a significant scientific question, and devotion in realizing the goal to its end – which will hopefully broaden knowledge for the benefit of humanity.
Beyond the Basics
‘People called me a dreamer,’ says Prof. Ada Yonath of the Structural Biology Department, recalling her decision to undertake research on ribosomes – the cell's protein factories. Solving the ribosome's structure would give scientists unprecedented insight into how the genetic code is translated into proteins; by the late 1970s, however, top scientific teams around the world had already tried and failed to get these complex structures of protein and RNA to take on a crystalline form that could be studied. Dreamer or not, it was hard work that brought results: Yonath and colleagues made a staggering 25,000 attempts before they succeeded in creating the first ribosome crystals, in 1980.
And their work was just beginning. Over the next 20 years, Yonath and her colleagues would continue to improve their technique. In 2000, teams at Weizmann and the Max Planck Institute in Hamburg, Germany – both headed by Yonath – solved, for the first time, the complete spatial structure of both subunits of a bacterial ribosome. Science magazine counted this achievement among the ten most important scientific developments of that year. The next year, Yonath's teams revealed exactly how certain antibiotics are able to eliminate pathogenic bacteria by binding to their ribosomes, preventing them from producing crucial proteins.
Yonath's studies, which have stimulated intensive research worldwide, have now gone beyond the basic structure. She has revealed in detail how the genetic information is decoded, how the ribosome's inherent flexibility contributes to antibiotic selectivity and the secrets of cross-resistance to various antibiotic families. Her findings are crucial for developing advanced antibiotics.
Prof. Ada Yonath's research is supported by the Helen and Milton A. Kimmelman Center for Biomolecular Structure and Assembly. Prof. Yonath is the Martin S. and Helen Kimmel Professor of Structural Biology.
The Weizmann Institute of Science in Rehovot, Israel, is one of the world's top-ranking multidisciplinary research institutions. Noted for its wide-ranging exploration of the natural and exact sciences, the Institute is home to 2,600 scientists, students, technicians and supporting staff. Institute research efforts include the search for new ways of fighting disease and hunger, examining leading questions in mathematics and computer science, probing the physics of matter and the universe, creating novel materials and developing new strategies for protecting the environment.
Weizmann Institute news releases are posted on the World Wide Web at http://wis-wander.weizmann.ac.il, and are also available at http://www.eurekalert.org/.
Two scientists from the Weizmann Institute of Science are among a list of 40 world-leading young scientists chosen by the journal Cell
Dr. Maya Schuldiner, born in 1975, joined the Weizmann Institute’s Molecular Genetics Department in 2008. She is married to Dr. Oren Schuldiner, also a scientist at the Weizmann Institute, and they have three children. Schuldiner’s laboratory uses advanced automation techniques in order to map the role of proteins and thoroughly understand the workings of cell organelles.
Schuldiner works eagerly in promoting both women in science as well as young scientists, and has established a course for students at the Institute, which provides training in both personal and managerial skills required to establish an independent laboratory.
Schuldiner states in her interview: “My personal philosophy is that my lab members are like my family. I spend as much time in the lab as I do at home, and I want to be happy when I am there. This philosophy guides many of the decisions that I make, for example, in choosing students to join my lab.”
Dr. Jacob Hanna was born and grew up in the Arab town Rameh to a family of doctors, and completed a joint physician/scientist program (MD/PhD). In 2011, Hanna joined the Weizmann Institute’s Molecular Genetics Department. His lab studies the changes that take place in the embryo at its earliest stage, which is responsible for turning the cluster of cells into all the different types of cells that make up the adult body. In addition, he explores in depth induced pluripotent stem (iPS) cells – mature body cells that undergo “reprogramming,” which gives them stem cell-like properties.
In recent years, his laboratory has been making a number of breakthroughs in this field, which will advance the possibility of future medical use of these cells as “spare parts” for damaged cells and tissues.
When asked during the interview about which scientists he admires: “I greatly admire my uncle, Dr. Nabil Hanna, an immunologist by training and the former chief scientific officer of Idec Pharmaceuticals (now Biogen-Idec, Inc.). He was behind the invention and development of Rituxan, the first monoclonal antibody approved for therapy in humans. As an eager student and a loving nephew, I was fortunate to be exposed to his adventure.”
Dr. Jacob Hanna's research is supported by Pascal and Ilana Mantoux, France/Israel; the Benoziyo Endowment Fund for the Advancement of Science; the Leona M. and Harry B. Helmsley Charitable Trust; the Sir Charles Clore Research Prize; Erica A. Drake and Robert Drake; the European Research Council; and the Fritz Thyssen Stiftung.